State Street Health Care Select ETF (XLV) Faces a Policy Reset
State Street Health Care Select ETF (XLV) investors face a less unified healthcare trade as Democrats prepare to take over Congress following the midterm elections, according to CNBC’s 2026-11-07 report. Jared Holz, who covers healthcare for Mizuho, expects likely gridlock between lawmakers to leave the sector without a clear policy direction. The investment implication is selective rather than uniformly negative: pharma and medtech may no longer deserve the same treatment.
Gridlock in this context means that divided lawmakers may struggle to change existing healthcare policy. Holz captured that constraint directly: “The next couple of years I really can't see too much happening.” His view does not establish what Congress will do; it frames the central risk as a lack of decisive change while investors reassess which healthcare subsectors can sustain momentum.
The State Street Health Care Select ETF (XLV) jumped 3% a day after Election Day, CNBC reported, then ended virtually flat for the week. That sequence shows an immediate positive reaction followed by no lasting weekly gain. It does not identify which policy expectation drove either move, so the price action cannot by itself confirm a durable change in the sector outlook.
XLV’s 32% Gain Meets a More Discriminating Market
State Street Health Care Select ETF (XLV) was up around 32% since President Trump took office in January 2025, beating the S&P 500 by almost 9 percentage points over that period. This is the strongest evidence in the record for healthcare’s established market strength. It also raises the standard for the next leg: an uncertain congressional outlook now confronts a sector that has already outperformed the broader index.
The tension is visible across the supplied time frames. A 3% advance a day after Election Day signaled an initially favorable response, while the virtually flat weekly finish showed that the gain did not translate into continued momentum through the end of the week. The longer record remains stronger, with XLV’s roughly 32% rise since January 2025 exceeding the S&P 500 by almost 9 percentage points.
Those figures support neither a blanket bearish call nor an assumption that prior leadership will continue. The long-period comparison favors healthcare; the weekly result and policy uncertainty argue against extrapolating that advantage without further evidence. For investors, the relevant distinction is between performance already recorded and the political conditions required to alter the next phase.
Jared Holz Draws a Line Between Pharma and Medtech
Holz’s most consequential allocation judgment was inside the sector. He said pharma was trading more expensively than tech for the first time in 20 years, then stated: “So, I backed away from pharma. I would look at medtech.” The comment links his caution on pharma to relative valuation and directs attention toward medtech, rather than rejecting healthcare as a whole.
That distinction matters because the evidence does not support treating every healthcare category as one trade. Holz said investors should pick and choose names, and he questioned the unusual breadth of healthcare categories moving together. His concern was not that every subsector must fall; it was that simultaneous strength across categories may obscure differences that should influence selection.
The potential medtech case remains conditional. Holz questioned whether healthcare regulations introduced over the past couple of years could be overturned in the near term. He indicated that if such a reversal occurred, investors might favor medical-device stocks at or near multi-year lows. The fact sheet does not confirm that regulations will change, identify individual device companies, or establish how their financial results would respond.
Pharma carries a different evidence problem. The first-time-in-20-years valuation comparison explains why Holz backed away, but it does not determine future returns or show that pharma must underperform medtech. Relative expense can sharpen sensitivity to disappointment; the supplied facts contain no earnings, revenue, trial, approval, or company-level data with which to test that risk.
The 2028 Conditions That Could Change the Healthcare Thesis
Holz identified the 2028 White House election as the more consequential political checkpoint. He said a Democratic victory could lead to some President Trump strategies being rolled back: “Then I think you see some of the Trump strategies rolled back.” He added that this scenario depends on Democrats retaining both the Senate and House, leaving several political conditions unresolved.
The constructive scenario is therefore specific. A Democrat wins the White House in 2028, Democrats retain the Senate and House, and policy changes create a more favorable setting for healthcare performance. None of those outcomes is confirmed, and the fact sheet does not establish which regulations might change or how quickly any reversal could reach healthcare companies.
The cautious scenario requires less political movement: likely gridlock persists, near-term regulatory reversals fail to materialize, and broad sector momentum remains difficult to sustain. In that setting, Holz’s preference for medtech over pharma remains a selection framework rather than a forecast of measured returns. XLV’s longer-term outperformance could continue, fade, or reverse; the available evidence cannot determine which path follows.
- Track the congressional configuration: the immediate question is whether likely gridlock prevents meaningful healthcare policy changes.
- Test the regulatory condition: any confirmed effort to overturn existing healthcare regulation would be the key evidence for Holz’s conditional medical-device view.
- Separate pharma from medtech: the first-time-in-20-years pharma valuation comparison supports scrutiny, while medtech is Holz’s preferred area under the stated conditions.
- Revisit the thesis around 2028: the White House result matters alongside whether Democrats retain the Senate and House; one outcome alone would not satisfy Holz’s scenario.
Market data check: State Street Health Care Select
State Street Health Care Select last traded near $184.8 (-0.06%). Our composite signal — blending price momentum and news flow — reads 🟡 neutral. Price momentum scores 50/100.
Data as of publication. Price via market feeds; for reference only, not investment advice.
📊 Analysis
Signal Neutral
Why XLV’s strong advance since January 2025 is balanced by an uncertain policy outlook and Jared Holz’s preference for selective medtech exposure over broad pharma ownership.
This article was independently written by OneDayTrading from public reporting. Read the original (CNBC)
